NEWS

PEPTOMYC SL Announces Treatment of First Patient with its Lead Compound OMO-103 in a Phase I/II Clinical Trial

peptomyc_20152021-07-26T10:46:09+00:0006 / 05 / 21|

Green light by the AEMPS to start clinical trials with OMO-103

peptomyc_20152021-07-26T10:46:59+00:0016 / 03 / 21|

Peptomyc Board of Directors appoints Giacomo Di Nepi as Chairman of the Board

peptomyc_20152021-01-04T18:37:58+00:0007 / 01 / 21|

Peptomyc steps forward as a Clinical Stage Biotech company

peptomyc_20152021-07-26T10:47:36+00:0021 / 12 / 20|

Peptomyc announces new equity financing round led by Aurora Science

peptomyc_20152020-12-16T09:23:02+00:0016 / 12 / 20|

Peptomyc receives 1.293.695,64 € from Spanish Mineco and European Commission joint fund

peptomyc_20152021-03-23T16:32:06+00:0021 / 10 / 20|

Peptomyc appoints Dr. Pepi Morales as Clinical Project Leader

peptomyc_20152021-07-26T10:48:12+00:0020 / 10 / 20|

Peptomyc’s CEO Laura Soucek recognized as a Life Science Leader by Pharma Intelligence

peptomyc_20152020-06-10T13:56:59+00:0009 / 06 / 20|

CEO explains her driving goal: “I want to eradicate cancer”

peptomyc_20152020-06-09T07:23:18+00:0008 / 06 / 20|

Flurry of scientific reviews published by Peptomyc

peptomyc_20152020-05-13T08:59:40+00:0012 / 05 / 20|